Evidence map›Paper›PMID 26379418›Full record

ArticleBiomarker insights2015

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.

Benjamin N Ostendorf, Hendrik Nogai, Claudia D Baldus, Thomas Burmeister, Renate Arnold

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarker insights, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Benjamin N OstendorfCharité University Medicine, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany.
Hendrik NogaiBayer Pharma AG, Berlin, Germany.
Claudia D BaldusCharité University Medicine, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany.
Thomas BurmeisterCharité University Medicine, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany. ; Labor Berlin, Hematology Division, Tumor Genetics, Berlin, Germany.
Renate ArnoldCharité University Medicine, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany.
Bayer (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The management of patients with chronic myeloid leukemia (CML) in advanced phases is challenging and requires the consideration of different treatment approaches, including targeted therapy with tyrosine kinase inhibitors, cytotoxic chemotherapy, and allogeneic stem cell transplantation. Here, we present the case of a patient with CML in mixed phenotype blast phase illustrating the integration of these strategies and demonstrating the need for close monitoring of treatment response in order to individually adjust treatment regimens.

Indexed as

BCR-ABLCMLmutationponatinibTKItransplantation

Identifiers

PMID26379418
PMCPMC4554357
OpenAlexW1946947417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.